FR13C0052I1 - - Google Patents

Info

Publication number
FR13C0052I1
FR13C0052I1 FR13C0052C FR13C0052I1 FR 13C0052 I1 FR13C0052 I1 FR 13C0052I1 FR 13C0052 C FR13C0052 C FR 13C0052C FR 13C0052 I1 FR13C0052 I1 FR 13C0052I1
Authority
FR
France
Prior art keywords
eye
reduce
vitreous
plasmin
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of FR13C0052I1 publication Critical patent/FR13C0052I1/fr
Application filed filed Critical
Application granted granted Critical
Publication of FR13C0052I2 publication Critical patent/FR13C0052I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02005—Chondroitin AC lyase (4.2.2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02019—Chondroitin B lyase (4.2.2.19)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Insulating Materials (AREA)
FR13C0052C 2002-12-06 2013-08-29 Vitreolyse pharmacologique en utilisant une plasmine raccourci Active FR13C0052I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228409.9A GB0228409D0 (en) 2002-12-06 2002-12-06 Pharmacological vitreolysis
PCT/US2003/038714 WO2004052228A2 (en) 2002-12-06 2003-12-05 Pharmacological vitreolysis

Publications (2)

Publication Number Publication Date
FR13C0052I1 true FR13C0052I1 (de) 2013-04-10
FR13C0052I2 FR13C0052I2 (fr) 2014-11-21

Family

ID=9949140

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0052C Active FR13C0052I2 (fr) 2002-12-06 2013-08-29 Vitreolyse pharmacologique en utilisant une plasmine raccourci

Country Status (25)

Country Link
US (11) US7547435B2 (de)
EP (3) EP2327415B1 (de)
JP (4) JP5426063B2 (de)
CN (1) CN100577202C (de)
AT (1) ATE534400T1 (de)
AU (1) AU2003300821C1 (de)
BE (1) BE2013C055I2 (de)
BR (2) BR0317033A (de)
CA (1) CA2508606C (de)
CY (2) CY1112561T1 (de)
DK (1) DK1581254T3 (de)
ES (2) ES2377965T3 (de)
FR (1) FR13C0052I2 (de)
GB (1) GB0228409D0 (de)
HK (1) HK1082419A1 (de)
HU (1) HUS1300040I1 (de)
IL (3) IL169008A (de)
LU (1) LU92273I2 (de)
MX (1) MXPA05006038A (de)
NO (4) NO333837B1 (de)
NZ (1) NZ541075A (de)
PT (2) PT2327416T (de)
SI (1) SI1581254T1 (de)
WO (1) WO2004052228A2 (de)
ZA (1) ZA200505193B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7152975B2 (en) * 2000-11-10 2006-12-26 Cooper Vision, Inc. Junctionless ophthalmic lenses and methods for making same
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CA2563675C (en) 2004-04-22 2012-08-28 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
JP4796787B2 (ja) 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2007005856A1 (en) * 2005-06-30 2007-01-11 Ista Pharmaceuticals, Inc. Use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US20070134230A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070134231A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
JP2009535371A (ja) * 2006-05-04 2009-10-01 フォベア、ファルマスティカル、ソシエテ、アノニム 血管新生性疾患の治療のための方法
PT2220221E (pt) * 2007-11-29 2015-04-16 Grifols Therapeutics Inc Plasmina modificada de forma recombinante
US20110142819A1 (en) * 2008-01-22 2011-06-16 Omnio Healer Ab Method of improving would healing
DK2257272T3 (da) * 2008-03-31 2014-01-20 Scarcell Therapeutics Fremgangsmåde til kosmetisk behandling af fotoaldring i hud
KR20110017903A (ko) 2008-06-04 2011-02-22 테일크리스 바이오쎄러퓨틱스 아이엔씨. 플라스민의 제조를 위한 조성물, 방법 및 키트
PL2403865T3 (pl) 2009-03-03 2016-01-29 Grifols Therapeutics Inc Sposoby wytwarzania plazminogenu
US8858924B2 (en) 2009-03-26 2014-10-14 Warsaw Orthopedic, Inc. Compositions and methods for treatment of hemorrhage
WO2011004011A1 (en) 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
US20110135626A1 (en) * 2009-12-08 2011-06-09 Alcon Research, Ltd. Localized Chemical Lysis of Ocular Tissue
KR20140015289A (ko) 2011-01-05 2014-02-06 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민 변이체
AU2012271562A1 (en) * 2011-06-17 2014-01-30 Allergan, Inc. D -serine for the treatment of visual system disorders
RU2604810C2 (ru) 2011-08-12 2016-12-10 Тромбодженикс Н.В. Варианты плазминогена и плазмина
RU2484795C2 (ru) * 2011-08-18 2013-06-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ индукции задней отслойки стекловидного тела с помощью миниплазмина
AU2012321082B2 (en) 2011-12-01 2015-03-12 Oxurion NV Improving trabeculectomy outcome
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
CA2871528A1 (en) 2012-04-24 2013-10-31 Thrombogenics N.V. Anti-pdgf-c antibodies
WO2014160281A2 (en) * 2013-03-14 2014-10-02 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
FR3034992A1 (fr) 2015-04-15 2016-10-21 Arcadophta Milieu plasmatique ex vivo autologue riche en plasmine et procede d'obtention
JP6749412B2 (ja) 2015-12-18 2020-09-02 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性神経損傷及びその関連疾患を予防または治療するための方法
CN108463240A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
RU2619991C1 (ru) * 2016-02-18 2017-05-22 Павел Владимирович Лыскин Способ лечения витреомакулярного тракционного синдрома
CA3013808A1 (en) 2016-03-10 2017-09-14 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
US20190314464A1 (en) 2016-12-15 2019-10-17 Talengen International Limited Novel method for treating diabetes
AU2018242882B2 (en) 2017-03-28 2021-08-12 Morinaga Milk Industry Co., Ltd. Novel Bifidobacterium genus bacterium
RU2674926C1 (ru) * 2018-02-01 2018-12-13 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. Способ оценки эффективности витреолизиса помутнений стекловидного тела
CN110361242B (zh) * 2019-08-14 2022-01-18 武汉赛维尔生物科技有限公司 一种用于眼球组织的固定液以及眼球组织制片的预处理方法
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658972A (en) * 1900-04-09 1900-10-02 Interchangeable Brake Beam Company Brake-beam.
US2624691A (en) 1946-04-22 1953-01-06 Parke Davis & Co Fibrinolysin derived from blood and methods of obtaining the same
DK98833C (da) 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
US3234106A (en) 1962-12-03 1966-02-08 Cutter Lab Soluble, purified profibrinolysin and fibrinolysin and method of producing same
US3950513A (en) 1965-12-03 1976-04-13 Novo Terapeutisk Laboratorium A/S Process of stabilizing therapeutically useful plasmin solutions
IT1194135B (it) * 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US5288485A (en) 1989-08-31 1994-02-22 Kao Corporation Vasodilating agent
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
US5288489A (en) 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
WO1994001128A1 (en) 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5304118A (en) * 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5973779A (en) 1996-03-29 1999-10-26 Ansari; Rafat R. Fiber-optic imaging probe
US6207066B1 (en) 1996-07-23 2001-03-27 Nuvue Technologies, L.L.C. Method for purification of a blood component
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5722428A (en) 1996-10-29 1998-03-03 Washington University Method for producing a posterior vitreous detachment
US6596725B2 (en) 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
EP0983084B1 (de) 1997-05-22 2007-01-10 Ista Pharmaceuticals, Inc. Verwendung von hyaluronidase zur herstellung eines augenpräparats zur glasskörperverflüssigung bei der behandlung von augenerkrankungen
ATE294865T1 (de) 1998-02-04 2005-05-15 Thromb X N V Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6462071B1 (en) 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US20040081643A1 (en) 1999-03-09 2004-04-29 Peyman Gholam A. Process for inhibiting vascular proliferation in the eye
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6585972B2 (en) 1999-03-09 2003-07-01 Gholam A. Peyman Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
AU1057901A (en) 1999-11-10 2001-06-06 Center For Advanced Science And Technology Incubation, Ltd. Method of preparing cell fraction containing hemangioblasts
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
WO2001085796A2 (en) * 2000-05-12 2001-11-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
DK1343903T3 (da) * 2000-12-21 2008-03-10 Thrombogenics Nv En gærekspressionsvektor og en fremgangsmåde til fremstilling af et rekombinant protein ved ekspression i en gærcelle
US20020139378A1 (en) * 2001-03-28 2002-10-03 Trese Michael T. Method for creating a separation of posterior cortical vitreous from the retina of the eye
FI20011132A0 (fi) 2001-05-30 2001-05-30 Innovationsagentur Markkeri hematopoieettisten kantasolujen tunnistamiseen
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
WO2004045558A2 (en) * 2002-11-18 2004-06-03 President And Fellows Of Harvard College Compositions and methods for treating thrombotic disorders
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

Also Published As

Publication number Publication date
NO2013016I2 (no) 2017-06-28
US20110300123A1 (en) 2011-12-08
NO20052988L (no) 2005-09-05
NO20052988D0 (no) 2005-06-17
US9186394B2 (en) 2015-11-17
JP5451533B2 (ja) 2014-03-26
ES2731625T3 (es) 2019-11-18
US20130195887A1 (en) 2013-08-01
IL202851A0 (en) 2011-07-31
US20130202613A1 (en) 2013-08-08
US7547435B2 (en) 2009-06-16
BR0317033A (pt) 2005-10-25
US8460655B2 (en) 2013-06-11
JP5426063B2 (ja) 2014-02-26
ES2377965T3 (es) 2012-04-03
US20080050356A1 (en) 2008-02-28
NO343759B1 (no) 2019-06-03
ATE534400T1 (de) 2011-12-15
ZA200505193B (en) 2007-08-29
EP2327415B1 (de) 2017-10-18
HK1082419A1 (en) 2006-06-09
PT1581254E (pt) 2012-02-06
EP2327415A1 (de) 2011-06-01
US20090081187A1 (en) 2009-03-26
US8747842B2 (en) 2014-06-10
LU92273I9 (de) 2019-01-15
BRPI0310144A8 (pt) 2018-04-24
IL169008A (en) 2011-08-31
US7803368B2 (en) 2010-09-28
DK1581254T3 (da) 2012-02-27
FR13C0052I2 (fr) 2014-11-21
JP2015131842A (ja) 2015-07-23
CY2013033I2 (el) 2015-11-04
US8834869B2 (en) 2014-09-16
SI1581254T1 (sl) 2012-05-31
WO2004052228A3 (en) 2004-10-07
CA2508606A1 (en) 2004-06-24
EP2327416A1 (de) 2011-06-01
NO20121169A1 (no) 2012-10-12
AU2003300821C1 (en) 2012-03-22
NZ541075A (en) 2008-02-29
JP2006518708A (ja) 2006-08-17
GB0228409D0 (en) 2003-01-08
EP1581254A2 (de) 2005-10-05
US20050118158A1 (en) 2005-06-02
CA2508606C (en) 2015-07-28
US9770494B2 (en) 2017-09-26
CY2013033I1 (el) 2015-11-04
US8383105B2 (en) 2013-02-26
CN100577202C (zh) 2010-01-06
BE2013C055I2 (de) 2023-03-07
CY1112561T1 (el) 2015-11-04
US20130302304A1 (en) 2013-11-14
US20090074739A1 (en) 2009-03-19
US20110171190A1 (en) 2011-07-14
EP1581254B1 (de) 2011-11-23
IL213838A0 (en) 2011-07-31
IL202851A (en) 2015-04-30
AU2003300821B2 (en) 2009-07-09
US20150064161A1 (en) 2015-03-05
EP2327416B1 (de) 2019-05-01
WO2004052228A2 (en) 2004-06-24
JP5996026B2 (ja) 2016-09-21
HUS1300040I1 (hu) 2013-08-15
PT2327416T (pt) 2019-07-04
AU2003300821A1 (en) 2004-06-30
CN1738641A (zh) 2006-02-22
US20080095753A1 (en) 2008-04-24
MXPA05006038A (es) 2006-03-08
LU92273I2 (fr) 2013-10-29
JP2010222369A (ja) 2010-10-07
US7914783B2 (en) 2011-03-29
NO333837B1 (no) 2013-09-30
JP2013241448A (ja) 2013-12-05
EP1581254A4 (de) 2007-03-28
US7867489B2 (en) 2011-01-11
NO2013016I1 (no) 2013-11-19
JP5739487B2 (ja) 2015-06-24
NO20121170A1 (no) 2012-10-12

Similar Documents

Publication Publication Date Title
FR13C0052I1 (de)
ATE426413T1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
ATE429914T1 (de) Verwendung von makroliden zur wiederherstellung der kornealempfindungen
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
EA200800337A1 (ru) Композиция и способ введения офтальмологически активных средств
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
MX2007010295A (es) Composiciones oftalmologicas novedosas y metodo para su uso.
ATE550015T1 (de) Verfahren und zusammensetzung zur behandlung von rhinitis
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
DK1263363T3 (da) Farvet viskoelastisk sammensætning
Yoon et al. Recurrent herpes simplex keratitis after verteporfin photodynamic therapy for corneal neovascularization
CY1106409T1 (el) Παραγωγα κινολινης
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
WO2002036096A3 (en) Non-aspirating transitional viscoelastics for use in surgery
RU2005104096A (ru) Способ лечения пролиферативной витреоретинопатии